INOVIO Submits Conditional Marketing Authorization Application to European Medicines Agency for VOCERYQ™ in Adults with Recurrent Respiratory Papillomatosis
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
INOVIO (Nasdaq: INO) submitted a conditional marketing authorization application to the European Medicines Agency for VOCERYQ in adults with recurrent respiratory papillomatosis (RRP). EU marketing authorization is pending. The application includes preclinical, clinical and manufacturing data. The European Commission granted VOCERYQ orphan drug designation for RRP in 2023, and an EMA committee certified that the manufacturing and nonclinical data it reviewed met standards used to evaluate an application.
The FDA granted accelerated approval on October 30, 2026 to reduce surgery frequency in adults with RRP. Continued U.S. approval may depend on confirmation of clinical benefit. INOVIO expects U.S. orders and shipments to begin approximately 60 days after FDA approval, with a full U.S. commercial launch expected in the first quarter of 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointFDA accelerated approval granted October 30, 2026, to reduce surgery frequency in adults with RRP
- Moderate pointVOCERYQ application submitted to the European Medicines Agency for conditional marketing authorization in adults with RRP
- Moderate point. Forward-looking: it has not happened yet and may not happen.U.S. commercial rollout expected to start with orders and shipments approximately 60 days after FDA approval, followed by a full launch in the first quarter of 2027
- Minor pointEMA committee certification confirmed that the manufacturing and nonclinical data reviewed met application evaluation standards
- Minor pointEU orphan drug designation granted by the European Commission for RRP in 2023
- Minor pointCELLECTRA device CE mark allows INOVIO to sell the device in the EU and other markets that recognize the mark
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.Continued U.S. approval may depend on verifying and describing clinical benefit in one or more confirmatory studies
- Minor pointEU marketing authorization for VOCERYQ remains pending
- Minor pointU.S. label warnings cover injection-site and procedure-related reactions and advise against use on the side of an implanted defibrillator or pacemaker, or where metal implants or skin abnormalities are present at the treatment site
Key Figures
- Prior close
- $1.63
- Nov 17, before the EMA application announcement
- Pre-publication 24-hour change
- +16.43%
- Market data from before the announcement
Historical Context
-
FDA accelerated approval established U.S. authorization before the European marketing application.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
conditional marketing authorization regulatory
advanced therapy medicinal product (atmp) certification regulatory
chemistry, manufacturing and controls (cmc) regulatory
accelerated approval regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- VOCERYQ™, the first FDA-approved plasmid DNA-based immunotherapy, received FDA accelerated approval on October 30, 2026
- Recurrent Respiratory Papillomatosis (RRP) is a rare, debilitating HPV-related disease with high unmet need in
Europe
"Building on the recent FDA approval of VOCERYQ, we believe there's significant opportunity to transform the treatment paradigm for RRP in
"Clinicians and patients alike understand that every surgery matters, because every surgery puts a patient's vocal cords at risk," said Frederik Dikkers, Professor emeritus of Otorhinolaryngology / Head and Neck Surgery at Amsterdam University Medical Center (Amsterdam UMC). "RRP affects patients around the world, and this submission is a meaningful step forward for those in
The CMA application is supported by a comprehensive set of preclinical, clinical, and manufacturing data, including results from INOVIO's clinical studies for VOCERYQ published in in 2025 in Nature Communications and The Laryngoscope. An additional analysis of the data was published in October 2026 in The Laryngoscope under the title DNA Immunotherapy (INO-3107) Long-Term Efficacy Supported by Enhanced Immunogenicity in HPV-6/11 RRP.
The European Commission granted Orphan Drug designation to INO-3107, now VOCERYQ, for the treatment of RRP in 2023. INO-3107 also received an Advanced Therapy Medicinal Product (ATMP) Certification from the EMA's Committee for Advanced Therapies (CAT) after review of chemistry, manufacturing and controls (CMC) and nonclinical data. This certification confirms that the data reviewed complies with the standards that would be used to evaluate a European marketing authorization application. INOVIO submitted the marketing authorization application using guidance from pre-submission meetings with EMA and the Rapporteurs. The CELLECTRA delivery device has a CE-mark in the EU, which allows INOVIO to commercialize the device in the EU and other geographies that recognize CE-marking.
The
About Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis (RRP) is a rare, debilitating disease caused primarily by HPV-6 and/or HPV-11. RRP is characterized by the development of small, wart-like growths, or papillomas, in the respiratory tract. While papillomas are generally benign, they can cause severe, life-threatening airway obstruction and respiratory complications. RRP can also significantly affect quality of life for patients by affecting the voice box, limiting the ability to speak effectively. Surgery to remove papillomas is the current standard of care for RRP; however, the papillomas often grow back. INOVIO's market research to date with patients and healthcare professionals indicates that a reduction of even one surgery matters, because every surgery poses a significant risk of causing permanent damage to the vocal cords and comes with potential costs to the patient, including adverse impacts to both quality of life and finances. Based on ongoing analysis of claims data, INOVIO believes there is a prevalent population of at least 25,000 patients with RRP in
About VOCERYQ™
VOCERYQ is a plasmid DNA-based immunotherapy designed to reduce the frequency of surgery for adults with RRP. VOCERYQ targets the root cause of RRP by generating an immune response using DNA plasmids that encode for HPV-6 and HPV-11 antigens. VOCERYQ is administered using the CELLECTRA® 5PSP delivery device. Following a standard-of-care surgical debulking of visible papilloma prior to the initial administration of VOCERYQ, no additional surgical intervention is required as part of the 9-week dosing regimen.
The FDA previously granted VOCERYQ both Orphan Drug and Breakthrough Therapy designations, and the European Commission granted INO-3107 Orphan Drug designation. The CELLECTRA delivery device has a CE-mark in the EU, which allows INOVIO to commercialize the device in the EU and other geographies that recognize CE-marking.
Learn more at www.voceryq.com.
INDICATION
VOCERYQ is indicated to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis.
This indication is approved under accelerated approval based on reduction in the frequency of surgical papilloma excisions. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory study(ies).
IMPORTANT SAFETY INFORMATION
Warnings & Precautions: Injection site reactions have occurred with VOCERYQ injection. Monitor patients for local site reactions for at least 30 minutes after treatment and manage accordingly.
Electroporation Related Adverse Reactions: Procedure-related effects including muscle contractions, transient bleeding, and vasovagal reactions may occur. Avoid use in patients with ipsilateral ICDs/pacemakers, metal implants or skin abnormalities at treatment site.
Adverse Reactions: Most common adverse reactions (incidence >
Please go to www.voceryq.com for full Prescribing Information, including Patient Information.
About INOVIO's DNA Medicines Platform
INOVIO's DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO's proprietary medical device, CELLECTRA. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that enable the body's cells to produce specific proteins to target and fight disease. INOVIO's proprietary CELLECTRA delivery devices are designed to optimally deliver its DNA medicines to the body's cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.
About INOVIO
INOVIO is a commercial-stage biotechnology company focused on developing innovative DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of DNA medicines that enable the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com and follow us on LinkedIn and X (formerly known as Twitter).
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our business, including the timing and success of preclinical studies and clinical studies; the ability to obtain and maintain regulatory approval of our product candidates, including in connection with our CMA application for VOCERYQ and that continued approval for VOCERYQ may be contingent on verification of clinical benefit in a confirmatory study; the potential benefits of VOCERYQ and the anticipated impact of VOCERYQ on treatment practices and outcomes for patients with RRP; the scope, progress and expansion of developing and commercializing our product candidates, including the anticipated availability and commercial launch timeline for VOCERYQ; our estimate of the prevalent population of patients with RRP in the United States; and our anticipated growth strategies. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical studies, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical studies will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.
Contacts
Media: Josephine Galatioto - ICR Healthcare, inoviopr@icrhealthcare.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, peter.vozzo@icrhealthcare.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-submits-conditional-marketing-authorization-application-to-european-medicines-agency-for-voceryq-in-adults-with-recurrent-respiratory-papillomatosis-302943334.html
SOURCE INOVIO Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.